We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

138 hedge funds and large institutions have $85.3M invested in Nektar Therapeutics in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 47 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $79.3M → $85.3M (+$5.99M)

0.17% more ownership

Funds ownership: 4.86% → 5.02% (+0.17%)

5% less funds holding

Funds holding: 146 → 138 (-8)

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

32% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 47

52% less call options, than puts

Call options by funds: $23K | Put options by funds: $48K

Holders
138
Holders Change
-8
Holders Change %
-5.48%
% of All Funds
2.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
32
Reduced
47
Closed
23
Calls
$23K
Puts
$48K
Net Calls
-$25K
Net Calls Change
-$300K

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$12M
2
TCM
Tang Capital Management
California
+$2.44M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.07M
4
Marshall Wace
Marshall Wace
United Kingdom
+$1.88M
5
LCM
Lynx1 Capital Management
Puerto Rico
+$1.13M

Top Sellers

1
SCM
Sio Capital Management
New York
-$4.02M
2
Invesco
Invesco
Georgia
-$3.32M
3
MAM
Monaco Asset Management
Monaco
-$2.86M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.62M
5
Millennium Management
Millennium Management
New York
-$2.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
AWM
126
AllSquare Wealth Management
New York
$165 – – –
SPIA
127
Steward Partners Investment Advisory
New York
$119 – – –
HI
128
Harbour Investments
Wisconsin
$92 – – –
FMII
129
Farmers & Merchants Investments Inc
Nebraska
$67 – – –
PGAM
130
Princeton Global Asset Management
New Jersey
$60 – – –
EARNEST Partners
131
EARNEST Partners
Georgia
$49 – – –
SL
132
Salomon & Ludwin
Virginia
$27 +$29 +3 New
GRP
133
Global Retirement Partners
California
$8 – – –
HNB
134
Huntington National Bank
Ohio
$1 – – –
SCM
135
Sio Capital Management
New York
– -$4.02M -466,359 Closed
Squarepoint
136
Squarepoint
New York
– -$469K -54,320 Closed
II
137
Inspire Investing
Idaho
– -$317K -36,770 Closed
YIH
138
Y-Intercept (HK)
Hong Kong
– -$179K -20,800 Closed
UBS AM
139
UBS AM
Illinois
– -$147K -13,911 Closed
CM
140
Caption Management
Oklahoma
– -$101K -11,694 Closed
PMEF
141
Point72 Middle East FZE
United Arab Emirates
– -$78.9K -9,143 Closed
OMC
142
Old Mission Capital
Illinois
– -$72.2K -8,370 Closed
LCM
143
Laurion Capital Management
New York
– -$48.7K -5,650 Closed
E
144
Ergoteles
New York
– -$21.6K -2,500 Closed
GCM
145
Gladius Capital Management
Illinois
– -$19.6K -2,276 Closed
GCM
146
Graham Capital Management
Connecticut
– -$13.9K -1,606 Closed
QT
147
Quantbot Technologies
New York
– -$12.1K -1,397 Closed
CAS
148
CTC Alternative Strategies
Illinois
– -$9.26K -1,073 Closed
VF
149
Virtu Financial
New York
– -$8K -912 Closed
XT
150
XTX Topco
Cayman Islands
– -$6.8K -788 Closed
3 4 5
6
7

NKTR Hedge Fund Activity: Q3 2023 in Review

138 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2023, worth a combined $85.3M — up 7.6% from $79.3M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of NKTR and 16 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 32 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12M. The largest seller was Sio Capital Management, exiting entirely with an estimated $4.02M sold.

  • 138 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2023, down from 146 in Q2 2023.
  • Funds reported $85.3M of Nektar Therapeutics stock for Q3 2023, up 7.6% quarter-over-quarter.
  • 16 funds opened new Nektar Therapeutics positions in Q3 2023 and 23 closed out, a net change of -7 holders.
  • The largest Nektar Therapeutics buyer in Q3 2023 was RA Capital Management, an estimated $12M added.
  • The largest Nektar Therapeutics seller in Q3 2023 was Sio Capital Management, an estimated $4.02M sold.

Based on aggregated 13F filings for Q3 2023.